Strategic Alliances
We recognize the importance of collaborating with other companies to accelerate the development and commercialization of potentially important products.
Historically, we have built and advanced our pipeline through a combination of internal development efforts and numerous in-licensing and out-licensing arrangements. (Please see below for brief descriptions.)
Consistent with our approach to date, we remain interested in learning about and exploring opportunities to work collaboratively with others.
Please contact Lee Bendekgey, Senior Vice President, CFO and General Counsel, if you have an opportunity to share.
Our Current Strategic Alliances
Archemix
We have collaboration with Archemix to develop and commercialize aptamers that have a short-acting anticoagulant effect. Under the terms of the agreement, Archemix will be responsible for discovery of short-acting aptamers for use in medical procedures, and Nuvelo will be responsible for development and worldwide commercialization of these aptamers.
For more information read the August 2006 press release.
Dendreon
We have a worldwide licensing agreement with Dendreon for novel anticoagulant, recombinant nematode anticoagulant protein c2 (rNAPc2) and all other rNAPc proteins.
For more information read the February 2004 press release.
Kirin Pharma Company, Limited
We have a development collaboration with Kirin to advance our Wnt pathway modulator, NU206. Under the terms of the agreement, Nuvelo leads worldwide development, manufacturing and commercialization and all expenses and operating profits are shared in a 60(Nuvelo)/40(Kirin) ratio.
For more information read the April 2005 press release.